Allarity Therapeutics Inc (ALLR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has a cash flow conversion efficiency ratio of -0.330x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.24 Million) by net assets ($9.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Allarity Therapeutics Inc for the company's overall valuation and market capitalisation.
Allarity Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Allarity Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Allarity Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allarity Therapeutics Inc ranked by their cash flow conversion efficiency. Explore ALLR cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chiangmai Frozen Foods Public Company Limited
BK:CM
|
-0.032x |
|
Truwin Co Ltd
KQ:105550
|
-0.059x |
|
Hansung Ent
KO:003680
|
0.030x |
|
Chemomab Therapeutics Ltd DRC
NASDAQ:CMMB
|
-1.292x |
|
Elspec
TA:ELSPC
|
0.028x |
|
OYAK Yatirim Ortakligi AS
IS:OYAYO
|
-0.012x |
|
A.S. Création Tapeten AG
F:ACWN
|
0.042x |
|
Karyon Industries Bhd
KLSE:0054
|
0.064x |
Annual Cash Flow Conversion Efficiency for Allarity Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Allarity Therapeutics Inc from 2015 to 2025. View latest Allarity Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.83 Million | $-14.82 Million | -1.508x | -2.64% |
| 2024-12-31 | $11.81 Million | $-17.35 Million | -1.469x | -131.71% |
| 2023-12-31 | $-2.75 Million | $-12.74 Million | 4.633x | +152.07% |
| 2022-12-31 | $1.89 Million | $-16.82 Million | -8.898x | -1010.55% |
| 2021-12-31 | $18.78 Million | $-15.05 Million | -0.801x | -196.70% |
| 2020-12-31 | $26.85 Million | $-7.25 Million | -0.270x | +44.18% |
| 2019-12-31 | $20.90 Million | $-10.11 Million | -0.484x | -218.50% |
| 2018-12-31 | $27.90 Million | $-4.24 Million | -0.152x | +95.55% |
| 2017-12-31 | $394.04K | $-1.34 Million | -3.413x | -346.16% |
| 2016-12-31 | $5.20 Million | $-3.98 Million | -0.765x | -85.86% |
| 2015-12-31 | $4.93 Million | $-2.03 Million | -0.412x | -- |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more